Quimioterapia con fármacos nuevos en el cáncer de pulmón de célula no pequeña avanzado [PDF]
, 2004 [spa] El cáncer de pulmón es el cáncer más frecuente en todo el mundo. A principio de la década de los 90 aparecieron varios fármacos con una actividad prometedora en cáncer de pulmón de célula no pequeña (CPCNP). El núcleo de esta tesis doctoral son dos
Cardenal Alemany, Felipe
core +7 more sources
Understanding cisplatin resistance using cellular models [PDF]
, 2007 Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resistance including changes in cellular drug accumulation, detoxification of the drug, inhibition of apoptosis and repair of the DNA adducts.
Davey, M +8 more
core +2 more sources
Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review [PDF]
, 2007 Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with ...
Pavlakis, Nick +8 more
core +2 more sources
Treating cisplatin-resistant cancer: a systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy [PDF]
, 2009 Objective: To examine the pre-clinical and clinical evidence for the use of oxaliplatin or paclitaxel salvage chemotherapy in patients with cisplatin-resistant cancer.
Pavlakis, Nick +5 more
core +2 more sources
Cisplatin-based chemotherapy of testicular cancer - Two decades after a major breakthrough [PDF]
, 2000 Two decades ago the introduction of cisplatin-based combination chemotherapy has dramatically improved the prognosis of patients with metastatic testicular cancer, At present 3 cycles of cisplatin, etoposide and bleomycin are considered as standard ...
Gerl, Arthur
core +1 more source
Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): A feasibility study [PDF]
, 2006 Background: Concurrent chemoradiotherapy has improved survival in inoperable stage III non-small cell lung cancer (NSCLC). This phase I trial was performed in order to establish a dose recommendation for oral vinorelbine in combination with cisplatin and
Schmidt, Michael +8 more
core +1 more source
ULTRASTRUCTURAL STUDY ON EFFECTS OF CISPLATIN ON VX2 CARCINOMA CELLS [PDF]
, 1990 The effects of intraarterial chemotherapy with cisplatin on rabbit VX2 carcinoma transplanted to the hind legs of animals were studied. Following intraarterial (IA) or intravenous (IV) administration of cisplatin (2.5 mg/kg), changes in the tumor cells ...
Kuo, Jeng HSIEH
core +1 more source
1-Hydroxy-8-methoxy-anthraquinon reverses cisplatin resistance by inhibiting 6PGD in cancer cells
Open Life Sciences, 2019 Targeting 6-phosphogluconate dehydrogenase (6PGD) can inhibit cancer cell proliferation and tumor growth. However, the relationship between 6PGD and cisplatin resistance still needs further study.
Zhang Huamin +4 more
doaj +1 more source
Glutamine protects against cisplatin-induced nephrotoxicity by decreasing cisplatin accumulation
Journal of Pharmacological Sciences, 2015 Cisplatin is a chemotherapeutic drug but induces acute kidney injury (AKI). Cisplatin-induced AKI depends on several signaling pathways leading to apoptosis in tubular epithelial cells.
Hyun-Jung Kim +9 more
doaj +1 more source
Equine sarcoids: Bovine Papillomavirus type 1 transformed fibroblasts are sensitive to cisplatin and UVB induced apoptosis and show aberrant expression of p53 [PDF]
, 2012 Bovine papillomavirus type 1 infects not only cattle but also equids and is a causative factor in the pathogenesis of commonly occurring equine sarcoid tumours.
Finlay, M. +14 more
core +1 more source